Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier

Drug Profile

Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier

Alternative Names: Macromolecular micelle paclitaxel; NK 105; Polymeric micelle paclitaxel

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoCarrier
  • Developer Nippon Kayaku
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Gastric cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 Sep 2017 Efficacy and adverse events data from a phase III trial in Breast cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 09 Feb 2017 Nippon Kayaku terminates phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Japan (IV) (JapicCTI-163257)
  • 01 Jan 2017 Nippon Kayaku completes a phase III trial in Breast cancer in Japan (IV) (NCT01644890)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top